Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.68 |
| ▸ | CTSS | P25774 | 8/20 | 0.64 |
| ▸ | CTSK | P43235 | 7/20 | 0.64 |
| ▸ | CTSB | P07858 | 3/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 2/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21800418 | 1.00 | ACE (0.68) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL7105276 | 1.00 | ACE (0.68) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL2603668 | 0.88 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL6516027 | 0.88 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL10536264 | 0.88 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL17688687 | 0.88 | ACE (0.70) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL19493067 | 0.87 | ACE (0.53) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL495795 | 0.86 | ACE (0.68) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL638877 | 0.86 | ACE (0.68) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL28462283 | 0.86 | CTSS (0.64) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4366834-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018046-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | ACE 1995/4885CTSS 3325/4885CTSK 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.